Circulating Tumor Cells (CTC) Detection System

An independently developed liquid biopsy platform for detecting circulating tumor cells with high sensitivity and specificity. This non-invasive blood-based test provides comprehensive tumor-related information for malignant tumor diagnosis and treatment guidance.

A next-generation circulating tumor cell detection system based on microfluidic chips and AI interpretation that captures cancer cells from a single blood sample. It enables non-invasive tumor monitoring, assists in lung nodule diagnosis, perioperative guidance, and treatment monitoring for precision oncology.

An independently developed platform for detecting circulating tumor DNA with high sensitivity and specificity compared to traditional detection methods. This liquid biopsy approach enables non-invasive, painless diagnosis through a single blood sample for comprehensive cancer patient support.

Circulating Tumor Cell (CTC) detection products that identify and analyze tumor cells in patient blood samples. These products provide critical diagnostic information for cancer monitoring and treatment planning.

Enumeration and characterization of viable tumor cells circulating in blood samples. Provides prognostic information and enables functional analysis of metastatic disease.

Point-of-care liquid biopsy platform for rapid cancer detection with 99% accuracy and high sensitivity. Delivers non-invasive screening results in minutes, enabling early diagnosis across multiple cancer types at a lower cost than conventional test kits.

Liquid-based cervical cytology system for automated sample preparation and microscopic analysis. The device enables standardized processing of cervical samples with improved sample quality and diagnostic accuracy.

Circulating tumor DNA detection and analysis system for cancer diagnosis and monitoring. Enables early cancer detection through blood-based liquid biopsy technology with high sensitivity and specificity.

Multiplex immunoassay platform for detecting circulating cancer biomarkers in blood samples. Facilitates early diagnosis and treatment response monitoring in oncology patients.

CRISPR-based molecular diagnostic test for tumor detection utilizing proprietary isothermal amplification and microfluidic integration. Enables rapid point-of-care testing with high sensitivity and specificity for oncology screening and monitoring applications.

In-vitro diagnostic test for detecting tumor markers and cancer-related antigens in blood and other biological samples. The test aids in cancer screening, diagnosis, and treatment monitoring.

Multi-biomarker screening solution for early-stage cancer identification. Analyzes blood samples to detect cancer-associated molecular signatures. Facilitates timely clinical intervention and improved patient outcomes.